AstraZeneca, Abbisko partner on lung cancer combination therapy trial

Abbisko and AstraZeneca team up on a Phase I/II NSCLC trial testing lumipodlin + TAGRISSO for EGFR-mutated, PD-L1+ patients—read the update now.